c-Jun NH(2)-terminal kinase inhibits targeting of the protein phosphatase calcineurin to NFATc1 by Chow, Chi-Wing et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
Open Access Articles Open Access Publications by UMMS Authors 
2000-06-24 
c-Jun NH(2)-terminal kinase inhibits targeting of the protein 
phosphatase calcineurin to NFATc1 
Chi-Wing Chow 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs 
 Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons 
Repository Citation 
Chow C, Dong C, Flavell RA, Davis RJ. (2000). c-Jun NH(2)-terminal kinase inhibits targeting of the protein 
phosphatase calcineurin to NFATc1. Open Access Articles. Retrieved from 
https://escholarship.umassmed.edu/oapubs/1436 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles 
by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
MOLECULAR AND CELLULAR BIOLOGY,
0270-7306/00/$04.0010
July 2000, p. 5227–5234 Vol. 20, No. 14
Copyright © 2000, American Society for Microbiology. All Rights Reserved.
c-Jun NH2-Terminal Kinase Inhibits Targeting of the Protein
Phosphatase Calcineurin to NFATc1
CHI-WING CHOW,1 CHEN DONG,2 RICHARD A. FLAVELL,2 AND ROGER J. DAVIS1*
Howard Hughes Medical Institute, Program in Molecular Medicine, Department of Biochemistry and Molecular Biology,
University of Massachusetts Medical School, Worcester, Massachusetts 01605,1 and Howard Hughes Medical Institute,
Section of Immunobiology, Yale University School of Medicine, New Haven, Connecticut 065202
Received 10 January 2000/Returned for modification 24 February 2000/Accepted 12 April 2000
The protein phosphatase calcineurin is a critical mediator of calcium signals during T-cell activation. One
substrate of calcineurin is the transcription factor NFATc1, which is retained in the cytoplasm of quiescent
cells. NFATc1 activation requires the translocation of the transcription factor into the nucleus, a process that
is mediated by calcineurin. This interaction with calcineurin requires a targeting domain (PxIxIT motif)
located in the NH2-terminal region of NFATc1. Here we demonstrate that the calcineurin targeting domain of
NFATc1 is phosphorylated and inactivated by the c-Jun NH2-terminal kinase (JNK). This disruption of
calcineurin targeting inhibits the nuclear accumulation and transcription activity of NFATc1 and accounts for
the observation that Jnk12/2 T cells exhibit greatly increased NFATc1-dependent nuclear responses.
The c-Jun NH2-terminal kinase (JNK) group of mitogen-
activated protein kinases is activated by treatment of cells with
cytokines or exposure to environmental stress (19). Gene dis-
ruption studies indicate that JNK protein kinases are required
for multiple biological processes (15, 23, 32, 41, 42). However,
the molecular mechanisms that account for the phenotypes
displayed by JNK knockout mice remain unclear. For example,
the disruption of the Jnk1 gene causes a severe defect in the
response of CD41 helper T (TH) cells to antigen-presenting
cells (15). Wild-type naive TH cells can differentiate to TH1 or
TH2 effector cells, which mediate inflammatory and humoral
responses, respectively. In contrast, Jnk12/2 CD4 TH cells
preferentially differentiate to TH2 effector cells and secrete
large amounts of the TH2 cytokines, including interleukin-4
(IL-4). As a consequence, these mice are highly susceptible to
infection with Leishmania. These effects of Jnk1 gene disrup-
tion were associated with increased nuclear accumulation of
the NFATc1 transcription factor (15), which is known to act at
the IL-4 promoter and is essential for TH2 responses (30, 44).
The phenotype of Jnk12/2 mice suggests that NFATc1 is neg-
atively regulated by JNK1 (15). However, this phenotype could
be a direct or an indirect consequence of Jnk1 gene disruption.
Transcription factor NFAT was first identified as an impor-
tant regulator of IL-2 gene expression (16, 20). More recently,
it has been established that NFAT contributes to the expres-
sion of several cytokines and participates in multiple physio-
logical processes (12, 31). In resting T cells, NFAT is restricted
to the cytoplasm (12, 31). Following T-cell activation, a sus-
tained increase in intracellular calcium (37) activates the phos-
phatase calcineurin (11, 21). The activated calcineurin dephos-
phorylates NFAT and leads to increased nuclear accumulation
(12, 31). The nuclear NFAT transcription factor then increases
the expression of target genes, including IL-2, IL-4, and Fas
ligand.
The interaction of calcineurin with NFAT is a critical ele-
ment in the signal transduction pathway that leads to increased
NFAT-dependent gene expression. Interestingly, this interac-
tion is mediated by a targeting domain (PxIxIT motif) that is
present in the NH2-terminal region of the NFAT transcription
factor (1, 2, 8). This targeting domain is required for efficient
NFAT activation in vivo. Furthermore, ectopic expression of
the targeting domain causes profound and specific inhibition of
NFAT-mediated gene expression in cultured cells (2, 8). Stud-
ies of transgenic mice also demonstrate inhibition of NFAT-
mediated gene expression caused by expression of the cal-
cineurin targeting domain (8). Together, these data indicate
that the calcineurin targeting domain is a critical component of
the regulatory mechanism that controls NFAT activity.
The purpose of this study was to examine the role of JNK1
in NFATc1 regulation. Since the phenotype of Jnk12/2 mice
suggests a correlation between the JNK1 signaling pathway
and NFATc1 (15), we tested whether NFATc1 is directly reg-
ulated by JNK1. We report that JNK1 binds and phosphory-
lates NFATc1 on sites located near the PxIxIT calcineurin
targeting domain. This phosphorylation inhibits the interaction
of calcineurin with the targeting domain and blocks nuclear
accumulation. This observation provides a molecular mecha-
nism for the observation of increased NFATc1 nuclear accu-
mulation in Jnk12/2 mice.
MATERIALS AND METHODS
Reagents. The IL-4 luciferase reporter plasmid (36) and the expression vectors
for calcineurin (28), NFATc1 (18), NFATc1-a (25), dominant negative NFAT
(dnNFAT) (8), and JNK signaling pathway components (7, 40) have been de-
scribed elsewhere. The NFATc1-b expression vector was constructed by cloning
a PCR-derived cDNA in the BamHI site of pSRa. Recombinant NFAT proteins
were expressed using the vector pGEX-5X1 (Amersham-Pharmacia Biotech) by
cloning cDNA fragments in the BamHI and NotI sites. Deletion and point
mutations were constructed by PCR and sequenced with an Applied Biosystems
machine. Bacterially expressed CRM1 was purified by glutathione (GSH) affinity
chromatography (43). The phosphospecific NFATc1 antibody prepared by im-
munization of rabbits with ovalbumin conjugated with glutaraldehyde to the
synthetic phosphopeptide Ala-Pro-Ala-Leu-Glu-Ser(P)-Pro-Arg-Ile-Glu-Ile-
Thr-Ser-Cys-Leu. The phosphospecific NFATc1 antibody was affinity purified
from the rabbit serum using standard techniques (17).
Binding assays. Cell extracts prepared using Triton-lysis buffer (20 mM Tris
[pH 7.4], 137 mM NaCl, 2 mM EDTA, 1% Triton X-100, 25 mM b-glycerophos-
phate, 1 mM sodium vanadate, 2 mM sodium pyrophosphate, 10% glycerol, 1
mM phenylmethylsulfonyl fluoride, 10 mg of leupeptin per ml) were incubated
(5 h at 4°C) with recombinant proteins (5 mg) prebound to 20 ml of GSH-
Sepharose. After three washes with Triton-lysis buffer, the bound proteins were
detected by protein immunoblot analysis.
* Corresponding author. Mailing address: Howard Hughes Med-
ical Institute Program in Molecular Medicine University of Massa-
chusetts Medical School, 373 Plantation St., Worcester, MA 01605.
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Kinase assays. Hemagglutinin epitope (HA)-tagged JNK1 was coexpressed
together with and without MLK3 in COS cells. Cell extracts were prepared with
Triton-lysis buffer 48 h after transfection. JNK1 immunocomplex kinase assays
were performed with recombinant NFATc1 proteins (1 mg) as the substrate (7).
Immunofluorescence assays. BHK cells were transfected using Lipofectamine
(Life-Technologies Inc.) according to the manufacturer’s protocol. Immunoflu-
orescence analysis was performed using cells transfected with an NFATc1-a
expression vector (1 mg) together with and without expression vectors for acti-
vated calcineurin (0.2 mg), MKK7 (0.2 mg) plus JNK1 (0.2 mg), dnJNK1 (0.5 mg),
or JIP-1 (0.3 and 0.7 mg). NFATc1 proteins were detected using monoclonal
antibody 7A6 (1:200; Affinity Bioreagents). The secondary antibody was Texas
red-conjugated anti-mouse immunoglobulin antibody (1:100; Jackson Immuno-
Research). Nuclei were visualized using 49,6-diamidino-2-phenylindole (Sigma).
RESULTS
JNK inhibits the nuclear accumulation of NFATc1-a. To
test whether JNK1 regulates NFATc1, we examined the effect
of activated JNK1 in transfection assays using cultured Jurkat
T cells. Treatment with phorbol ester and ionomycin caused a
transient increase in JNK protein kinase activity which re-
turned to basal levels within 1 h (24, 35). At later times, a large
increase in the expression of NFATc1 was detected (Fig.
1A). Cell fractionation studies demonstrated the presence
of NFATc1 in the nucleus. Expression of activated JNK1 did
not alter the expression of NFATc1 but did cause a marked
reduction in the amount of nuclear NFATc1 (Fig. 1A). In
contrast, expression of dnJNK1 increased the amount of
nuclear NFATc1 caused by anti-CD3 stimulation (data not
shown). Transfection assays were performed to examine the
effect of JNK1 on transcription activity using an IL-4 promoter
reporter gene. Activated JNK1, like dnNFAT, strongly inhib-
ited reporter gene expression (Fig. 1B). Since constitutively
nuclear mutant NFATc1 caused greatly increased reporter
gene expression (data not shown), it is likely that the effect of
activated JNK1 to inhibit reporter gene expression (Fig. 1B)
was the consequence of the decreased amount of nuclear
NFATc1 (Fig. 1A). Together, these data demonstrate that
JNK1 functions as an inhibitor of the endogenous NFATc1
transcription factor expressed by Jurkat T cells.
Several alternatively spliced variant forms of NFATc1 have
been described (9, 10, 18, 25, 26, 33). The major isoform
expressed by T cells has been identified as NFATc1-a (25,
33). We therefore performed further analysis of the regulation
of NFATc1 by JNK using the NFATc1-a isoform.
JNK phosphorylates NFATc1-a. The JNK1 protein kinase
binds and phosphorylates its substrates (19). Deletion analysis
and in vitro binding assays indicated that NFATc1-a residues
126 to 138 are required for the binding of NFATc1-a to JNK1
(Fig. 2). In contrast, NFATc1-a phosphorylation by JNK1 was
reduced by truncation at residue 171 and was eliminated by
truncation at residues 126 (Fig. 3A). Phosphoamino acid anal-
ysis demonstrated the presence of phosphoserine (data not
shown). Four potential JNK1 phosphorylation sites (Ser-Pro
motifs) were identified. Mutational analysis indicated that both
Ser117 and Ser172 were phosphorylated by JNK1. Replacement
of either Ser117 or Ser172 with Ala reduced phosphorylation by
JNK1, while the replacement of both Ser117 and Ser172 elimi-
nated phosphorylation by JNK1 (Fig. 3B). Together, these data
demonstrate that JNK1 binds NFATc1-a and phosphorylates
both Ser117 and Ser172 in vitro. The JNK1 phosphorylation site
Ser172, but not Ser117, is conserved in the related transcrip-
tion factor NFATc3 (7). Comparative tryptic phosphopeptide
mapping of NFATc1-a isolated from [32P]phosphate-labeled
cells indicated that two phosphopeptides present in maps of
wild-type NFATc1-a were absent in maps of mutated [Ala117
Ala172] NFATc1-a, suggesting that Ser117 and Ser172 may be
phosphorylated in vivo (data not shown). To test this hypoth-
esis, we prepared a phospho-NFATc1 antibody and performed
immunoblot analysis of NFATc-a. The phospho-NFATc1 anti-
body specifically detected phosphorylation on Ser117 (Fig. 4A).
Activation of endogenous JNK caused increased NFATc1-a
phosphorylation (Fig. 4B). Overexpression of the scaffold pro-
tein JIP-1 causes profound inhibition of JNK (13, 39) and
inhibited NFATc1-a phosphorylation (Fig. 4B). Together,
these data suggest that NFATc1-a is a JNK substrate in vivo.
Phosphorylation by JNK inhibits the nuclear accumulation
of NFATc1-a. Studies of Jurkat T cells demonstrated that
activated JNK1 inhibited the calcium-stimulated nuclear ac-
cumulation of NFATc1 (Fig. 1A). This observation was con-
firmed by immunofluorescence analysis of the subcellular
distribution of NFATc1-a. Activated JNK1 inhibited the cal-
cineurin-stimulated nuclear accumulation of NFATc1-a (Fig.
5A and B). This effect of activated JNK1 to inhibit NFATc1-a
nuclear accumulation was blocked by overexpression of pro-
FIG. 1. JNK1 inhibits NFAT activity in T cells. (A) Activation of JNK1
inhibits NFATc1 nuclear localization. Jurkat T cells were transfected without
(empty expression vector; Control) and with MKK7 plus JNK1 (JNK). After
16 h, the cells were stimulated without (2) and with (1) ionomycin (I; 2 mM)
plus PMA (P; 100 nM) for 6 h. Nuclear extracts were isolated (14), and NFATc1
was examined by protein immunoblot analysis using monoclonal antibody 7A6
(Affinity Bioreagents). Similar data were obtained in three independent experi-
ments. (B) Activated JNK inhibits NFAT transcription activity. Jurkat T cells
were transfected with an IL-4 promoter reporter gene (firefly luciferase) plasmid
together without (Control) and with MKK7 plus JNK1 (JNK) or dnNFAT.
Transfection efficiency was monitored by measurement of Renilla luciferase
activity. The cells were stimulated without (h) and with (n ) ionomycin (2 mM)
plus PMA (100 nM) for 6 h. The data are presented as fold activation by in
treated compared to untreated cells (mean 6 standard deviation; n 5 4).
FIG. 2. Interaction of JNK1 with NFATc1-a. Lysates were prepared from
COS cells transfected with HA-JNK1, and the binding of HA-JNK1 to immobi-
lized recombinant NFATc1-a was examined. The effect NFATc1-a deletions is
shown. The location of the JNK binding domain (JBD) and PxIxIT motif on
NFATc1-a are illustrated schematically. Potential JNK phosphorylation sites
(SP) are indicated.
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teins that can inhibit JNK signaling, including dnJNK1 (Figure
5C) and the scaffold protein JIP-1 (Fig. 5D). Together, these
data demonstrate that activated JNK1 regulates NFATc1-a
nuclear accumulation.
To test whether the phosphorylation of NFATc1-a is mech-
anistically relevant to the regulation of NFATc1-a nuclear
accumulation by JNK1, we examined the effect of the replace-
ment of the NFATc1-a phosphorylation sites with Ala resi-
dues. The subcellular distribution of the wild-type and mutated
NFATc1-a proteins was examined by immunofluorescence
analysis. Mutations at both phosphorylation sites (Ser117 and
Ser172) altered the subcellular distribution of NFATc1-a. The
mutated [Ala117 Ala172] NFATc1-a protein was found to be
present in the nucleus under basal conditions and was not reg-
ulated by activated JNK1 (Fig. 5A and B). Mutation at either
Ser117 or Ser172 was sufficient to increase the nuclear accumu-
lation of NFATc1-a. To examine whether the altered nuclear
accumulation of the phosphorylation-defective NFATc1-a
proteins was relevant to transcription activity, we performed
transfection assays of Jurkat T cells with an IL-4 promoter
reporter plasmid (Fig. 5E). Expression of wild-type NFATc1-a
using Jurkat T cells caused a large increase in phorbol myris-
tate acetate (PMA)-ionomycin-stimulated IL-4 promoter re-
porter gene expression, which was inhibited by coexpression of
activated JNK1. In contrast, the [Ala117 Ala172] NFATc1-a
protein caused increased reporter gene expression in the ab-
sence of PMA-ionomycin stimulation and was not inhibited by
activated JNK1 in the presence or absence of PMA-ionomycin
(Fig. 5E). Together, these data demonstrate that the JNK1
phosphorylation sites (Ser117 and Ser172) are required for the
regulation of both nuclear accumulation and transcription ac-
tivity of NFATc1-a by JNK1.
JNK selectively regulates NFATc1 isoforms. We have pre-
viously reported that recombinant NFATc1 is not regulated by
JNK1 (7). This conclusion markedly differs from the results
obtained from the analysis of endogenous NFATc1 expressed
by Jurkat T cells (Fig. 1). Several alternatively spliced variant
forms of NFATc1 have been described, including molecules
with three distinct COOH-terminal domains (9, 10) and three
distinct NH2-terminal domains (18, 25, 26, 33). The isoforms
FIG. 3. Phosphorylation of NFATc1-a by JNK1 in vitro. (A) JNK1 phos-
phorylates NFATc1-a. Immunocomplex kinase assays were performed using
JNK1 activated without (Control; 2) or with (1) MLK3 using recombinant
NFATc1-a as the substrate. Phosphorylated NFATc1-a was detected by auto-
radiography and quantitated by PhosphorImager (Molecular Dynamics) analysis.
(B) JNK phosphorylates NFATc1-a on Ser117 and Ser172. Wild-type and mutant
NFATc1-a proteins (residues 1 to 202) were phosphorylated by JNK1 in vitro.
The effects of JNK1 activation by MLK3 and the replacement of Ser117 and
Ser172 with Ala were examined.
FIG. 4. Phosphorylation of NFATc1-a in vivo. (A) NFATc1-a was coex-
pressed with MKK7 plus JNK1 in COS cells. The effect of replacement of Ser117
and Ser172 with Ala residues was investigated. Cell lysates were examined
by protein immunoblot analysis by sequentially probing with anti-phospho-
NFATc1-a and anti-NFATc1. A nonspecific band was detected by the phospho-
NFATc1-a antibody immediately above the NFATc1-a band. (B) NFATc1-a was
coexpressed without (2) and with (1) the JNK inhibitor JIP-1 in COS cells. The
cells were treated without (2) and with (1) UV-C radiation (80 J/m2) and
harvested after 30 min. The effect of replacement of the JNK phosphorylation
sites (Ser117 and Ser172) with Ala was examined. The NFATc1-a proteins were
detected by protein immunoblot analysis by sequentially probing with anti-phos-
pho-NFATc1-a and anti-NFATc1.
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with distinct NH2-terminal domains correspond to NFATc1
(18), NFATc1-a (25), and NFATc1-b (26, 33). NFATc1-a is
the major isoform expressed by T cells (25, 33).
To test whether JNK may differentially interact with NFATc1
isoforms, we expressed the NH2-terminal region of NFATc1,
NFATc1-a, and NFATc1-b in bacteria as glutathione S-trans-
ferase (GST) fusion proteins. The purified GST-NFAT pro-
teins were immobilized on GSH-agarose. Control experiments
demonstrated that JNK1 did not bind to immobilized GST
(Fig. 6A). However, strong binding of JNK1 to NFATc1-a and
NFATc1-b was detected. In contrast, NFATc1 bound poorly
to JNK1. In vitro immune complex protein kinase assays us-
ing epitope-tagged JNK1 demonstrated that there was greater
phosphorylation of NFATc1-a and NFATc1-b than of NFATc1
(Fig. 6B). These data suggest that JNK1 may be selectively
targeted to NFATc1-a and NFATc1-b.
We compared the subcellular distribution of NFATc1,
NFATc1-a, and NFATc1-b by immunofluorescence analysis
(Fig. 6C). In control cells, NFATc1-a and NFATc1-b were
located predominantly in the cytoplasm, but a large fraction of
NFATc1 was found in the nucleus. Expression of activated
JNK1 caused no significant change in the subcellular distribu-
tion of these NFATc1 isoforms. In contrast, activated calci-
neurin caused increased nuclear localization of all three
NFATc1 isoforms. Activated JNK1 suppressed the calcineurin-
stimulated nuclear accumulation of NFATc1-a and NFATc1-b
but not the NFATc1 isoform.
Taken together, these data indicate that JNK1 negatively reg-
ulates the NFATc1-a and NFATc1-b isoforms but not NFATc1.
It is likely that the markedly decreased binding of JNK1 to
NFATc1 (Fig. 6A) compared to the other NFATc1 isoforms
contributes to this differential regulation. As NFATc1-a is the
major isoform expressed by T cells (25, 33), these data indicate
that JNK1 may function as an inhibitor in T cells. The pheno-
type of Jnk12/2 mice is consistent with the hypothesis (15).
Phosphorylation by JNK inhibits targeting of NFATc1-a by
the phosphatase calcineurin. JNK1 phosphorylates NFATc1-a
on Ser117 and Ser172 (Fig. 3). Ser117 of NFATc1-a is located
adjacent to the previously identified calcineurin targeting do-
main (PxIxIT motif) (1, 2, 8). We hypothesized that phosphor-
ylation on Ser117 may regulate the targeting of NFATc1-a to
calcineurin. However, the proximity of Ser117 to the calcineurin
targeting domain suggests that Ser117 may represent a poten-
tial substrate for dephosphorylation by calcineurin. We there-
FIG. 5. JNK1 inhibits the nuclear accumulation of NFATc1-a. (A and B) Subcellular distribution of NFATc1-a, examined by immunofluorescence analysis in
transfected BHK cells. The NFAT proteins (red; right) and nucleus (blue; left) were visualized (A). The effects of expression of a constitutively activated calcineurin
(DCN) and MKK7 plus JNK1 (JNK) were examined. Arrowheads indicate the nuclei of cells expressing transfected proteins. The data were quantitated (B) following
examination of 300 transfected cells and are presented as the percentage of cells with nuclear NFATc1-a (mean 6 standard deviation [SD]; n 5 3). (C) Effect of dnJNK
on the subcellular distribution of NFATc1-a, examined by immunofluorescence analysis. The effects of expression of constitutively activated calcineurin (DCN) and
MKK7 plus JNK1 (JNK) were examined. The percentage of cells with nuclear NFATc1-a is presented (mean 6 SD; n 5 3). (D) Effect of JIP-1 on the subcellular
distribution of NFATc1-a, examined by immunofluorescence analysis. The percentage of cells with nuclear NFATc1-a is presented (mean 6 SD; n 5 3). The effects
of increasing amounts of JIP-1 expression vector (0.3 and 0.7 mg) and the expression of constitutively activated calcineurin (DCN) and MKK7 plus JNK1 (JNK) were
examined. (E) Mutational removal of Ser117 and Ser172 potentiates NFATc1-a transcription activity on the IL-4 promoter. Wild-type and [Ala117 Ala172] NFATc1-a
were cotransfected with an IL-4 reporter plasmid in the absence (Untreated) and presence of MKK7 plus JNK1 (JNK). The cells were stimulated without (Untreated)
and with PMA (P; 100 nM) plus ionomycin (I; 2 mM) for 16 h. The data are presented as fold activation compared to an untreated control (cells transfected without
an NFATc1-a expression vector).
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fore examined the kinetics of calcineurin-mediated dephos-
phorylation of JNK1-phosphorylated NFATc1-a. This analysis
demonstrated that Ser172 (and not Ser117) was preferentially
dephosphorylated by calcineurin in vitro (Fig. 7A). Thus, the
PxIxIT targeting motif that binds calcineurin facilitates the
dephosphorylation of distal (e.g., Ser172) but not proximal
(e.g., Ser117) NFAT phosphorylation sites. These data support
the hypothesis that Ser117 may regulate the targeting function
of the NFATc1-a PxIxIT motif. To test this hypothesis, we
examined the effect of NFATc1-a phosphorylation by JNK1 on
the interaction of NFATc1-a with calcineurin. Phosphoryla-
tion caused a marked reduction in the binding of calcineurin to
NFATc1-a (Fig. 7B). Mutational analysis demonstrated that
the phosphorylation of Ser117, but not Ser172, was required for
the regulation of calcineurin binding by JNK1. To confirm that
phosphorylation on Ser117 regulates calcineurin binding, we
performed competition assays using a synthetic PxIxIT peptide
with either Ser117 or phospho-Ser117 (Fig. 7C). Binding assays
confirmed that the Ser117 PxIxIT peptide disrupted calcineurin
binding in a dose-dependent manner. In contrast, calcineurin
binding to NFATc1-a was not inhibited by the phospho-Ser117
PxIxIT synthetic peptide. Together, these data demonstrate
that Ser117 phosphorylation inhibits the function of the cal-
cineurin targeting domain of NFATc1-a.
CRM1 interacts with dephosphorylated NFATc1-a. The ex-
port of NFAT from the nucleus is mediated, in part, by a
mechanism that involves the GTPase Ran and the exportin
CRM1 (22). One CRM1 binding site on NFATc3 is located
adjacent to the calcineurin targeting domain (45). Indeed,
binding of NFATc3 to calcineurin competes with the binding
to CRM1 (45). Since NFATc1-a phosphorylation inhibits the
binding of calcineurin (Fig. 7), we examined whether phos-
phorylation affected the interaction of NFATc1-a with CRM1.
Binding assays were performed using immobilized GST-CRM1
and lysates prepared from COS cells expressing NFATc1-a
(Fig. 8). We found that NFATc1-a bound to CRM1. The
binding to CRM1 was increased when the NFATc1-a was
coexpressed with activated calcineurin (Fig. 8A). This obser-
FIG. 6. Differential regulation of NFATc1 isoforms by JNK. (A) The NH2-terminal regions of NFATc1 (18), NFATc1-a (25), and NFATc1-b (26, 33) are illustrated
schematically. The PxIxIT motif (hatched box), the NFAT homology domain (NHD), and the alternative NFATc1 NH2 termini are indicated. Immobilized GST,
GST-NFATc1 (residues 1 to 126), GST–NFATc1-a (residues 1 to 202), and GST–NFATc1-b (residues 1 to 189) was incubated with extracts prepared from COS cells
transfected with HA-JNK1. The binding of HA-JNK1 was examined by immunoblot analysis. (B) Comparison of the phosphorylation of NFATc1 isoforms by JNK1
in vitro. Immunocomplex kinase assays were performed using Flag epitope-tagged JNK1 activated without (2) and with (1) MLK3, using recombinant NFATc1
isoforms as the substrate. (C and D) Subcellular distribution of NFATc1 isoforms, examined by immunofluorescence analysis in transfected BHK cells. The NFAT
proteins (red; right) and nucleus (blue; left) were visualized (C). The effect of constitutively activated calcineurin (DCN) or MKK7 plus JNK1 (JNK) was examined.
Arrowheads indicate the nuclei of cells expressing transfected proteins. The data were quantitated (D) following examination of 300 transfected cells and are presented
as the percentage of cells with nuclear NFATc1 (mean 6 standard deviation; n 5 3).
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vation suggests that calcineurin-mediated dephosphorylation
of NFATc1-a increases binding to CRM1.
To test whether phosphorylation of NFATc1-a on the JNK
sites altered CRM1 binding, we examined the effect of replace-
ment of Ser117 and Ser172 with Ala residues. A marked increase
in NFATc1-a binding to CRM1 was detected for the mutated,
phosphorylation-defective NFATc1-a protein (Fig. 8B). These
data suggested that phosphorylation on Ser117 and Ser172 may
inhibit binding to CRM1. To test this hypothesis, we examined
the effect of inhibiting JNK signaling on the binding of NFATc1-
a to CRM1. Overexpression of the scaffold protein JIP-1 causes
a profound inhibition of JNK signaling (13, 39). JIP-1 in-
creased the binding of CRM1 to wild-type [Ser117 and Ser172]
NFATc1-a but not to the mutated phosphorylation-defective
[Ala117 and Ala172] NFATc1-a. These data indicate that phos-
phorylation regulates the interaction between CRM1 and
NFATc1-a.
DISCUSSION
In this study we demonstrate that the JNK signaling pathway
plays a key role as a negative regulator of substrate targeting by
the phosphatase calcineurin. The phosphorylation of NFATc1
by JNK provides a mechanism whereby NFATc1-driven re-
sponses can be terminated, which can set a threshold for a
given response. This is likely to be important for normal cel-
lular physiology. Indeed, we have demonstrated that Jnk12/2
mice displayed enhanced TH2 responses due to increased nu-
clear localization of NFATc1 (15). Conversely, activation of
the JNK1 signaling pathway inhibits IL-4 gene promoter activ-
ity (Fig. 1). Thus, JNK1 functions in TH2 cells to suppress the
expression of cytokines that enhance TH2 responses (e.g., IL-4)
which would otherwise lead to the generation of an unbalanced
TH cell immune response to pathogens. Together, the genetic
evidence and biochemical analysis that we present strongly
support the hypothesis that JNK is a physiologically relevant
regulator of NFATc1 function.
Recent studies have established that the formation of pro-
tein complexes is a critical aspect of signal transduction mech-
anisms that ensures both efficiency and specificity in vivo (27,
40). An example of the formation of signaling complexes is the
requirement of targeting domains for the interaction of protein
kinases and protein phosphatases with their substrates. We
demonstrate that such interactions are subjected to regulation
by phosphorylation. Our results indicate that phosphorylation
of NFATc1 by JNK inhibits targeting of the phosphatase
calcineurin. Since calcineurin functions to induce the nu-
clear accumulation of NFAT, phosphorylation by JNK in-
hibits NFATc1 activation. Inhibition of phosphatase targeting
FIG. 7. JNK1 inhibits the binding of calcineurin to NFATc1-a. (A) Compar-
ison of calcineurin-stimulated dephosphorylion of Ser117 and Ser172. Recombi-
nant NFATc1-a (residues 1 to 202) was phosphorylated by JNK1 in vitro and
incubated (30 min at 30°C) in 50 mM HEPES (pH 7.4)–2 mM MnCl2–0.5 mM
EDTA–15 mM 2-mercaptoethanol–0.1 mg of bovine serum albumin per ml
together with calmodulin (250 U) and indicated amounts of calcineurin (Sigma).
The phosphorylated NFATc1-a was detected after sodium dodecyl sulfate-poly-
acrylamide gel electrophoresis by autoradiography and was quantitated by Phos-
phorImager (Molecular Dynamics) analysis. Dephosphorylation at Ser117 and
Ser172 was examined using [Ala172] and [Ala117] NFATc1-a, respectively. (B)
Phosphorylation of NFATc1-a by JNK1 inhibits the binding of NFATc1-a to the
phosphatase calcineurin. Recombinant NFATc1-a (residues 1 to 202) was phos-
phorylated by JNK1 in vitro. The NFATc1-a proteins were immobilized on
GSH-Sepharose, incubated with cell extracts, and washed; bound calcineurin was
detected by protein immunoblot analysis. The effect of replacement of the
NFATc1-a phosphorylation sites (Ser117 and Ser172) with Ala was examined. (C)
Phosphorylation of Ser117 inhibits calcineurin binding to NFATc1-a. Immobi-
lized recombinant NFATc1-a (residues 1 to 202) was incubated with cell extracts,
and the binding of calcineurin was examined by protein immunoblot analysis.
Competition analysis was performed by investigating the effects of various con-
centrations (0, 0.7, 1.4, 7, and 14 mM) of a synthetic peptide corresponding to the
PxIxIT motif which mediates the targeting of calcineurin to NFATc1-a. The
effect of the phosphorylation of the synthetic peptide on Ser117 was examined. FIG. 8. NFATc1-a binding to CRM1 is regulated by phosphorylation. (A)
Activated calcineurin increases the binding of NFATc1-a to CRM1. NFATc1-a
was expressed without (2) or with (1) activated calcineurin (DCN) in COS cells.
Recombinant CRM1 was immobilized on GSH-Sepharose, incubated with the
COS cell extracts, and washed; bound NFATc1-a was detected by protein im-
munoblot analysis. (B) JNK phosphorylation inhibits the binding of NFATc1-a
to CRM1. The effect of replacement of the JNK phosphorylation sites (Ser117
and Ser172) on the binding of NFATc1-a to CRM1 was examined. The effect of
JNK inhibition was investigated by overexpression of the scaffold protein JIP-1.
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is a novel mechanism of regulation by a mitogen activated
protein kinase. However, this regulatory mechanism may also
be applicable to other signaling systems that are regulated by
phosphorylation.
Our study further establishes the importance of the PxIxIT
motif in the regulation of calcineurin targeting to NFAT. Pre-
vious studies demonstrated that the PxIxIT motif was required
for efficient activation of NFAT by calcineurin (1) and that
ectopic expression of the PxIxIT motif inhibits NFAT-medi-
ated gene expression in both cultured cells (2, 8) and trans-
genic mice (8). Here we demonstrate that the function of the
PxIxIT targeting motif can be regulated by phosphorylation.
Our data suggest that regulated substrate targeting repre-
sents a potential approach for the design of novel therapeu-
tic agents.
Coordination of NFAT binding to calcineurin and CRM1. It
is established that both the phosphatase calcineurin and the
exportin CRM1 bind to NFAT (22, 45). Studies of NFATc3
indicate that one of the binding sites for CRM1 is located
adjacent to the calcineurin binding site (45). Binding to cal-
cineurin is calcium dependent and competes with the binding
to CRM1. The binding affinity of NFATc3 for calcineurin/
Ca21 is higher than that for CRM1 (45). These observations
have led to the conclusion that calcineurin acts, in part, to
induce nuclear accumulation of NFATc3 by suppressing the
CRM1-dependent export pathway (45). It is likely that other
NFAT proteins are regulated by similar mechanisms.
Our studies of NFATc1-a indicate that phosphorylation by
JNK causes inhibition of calcineurin binding (Fig. 7). This
inhibited interaction with calcineurin may account for the ef-
fect of activated JNK to prevent calcium-mediated nuclear
accumulation of NFATc1-a (Fig. 5). Since calcineurin and
CRM1 compete for binding to NFAT, we considered that the
effect of JNK to decrease calcineurin binding might lead to
increased CRM1 binding. This potential mechanism suggests
that increased CRM1-mediated export of NFATc1-a from the
nucleus may contribute to the effect of JNK signaling to inhibit
nuclear accumulation of NFATc1-a. However, measurement
of CRM1 binding demonstrated that JNK phosphorylation
inhibited the binding of both CRM1 and calcineurin (Fig. 7
and 8). These data suggest that the primary action of JNK to
prevent the nuclear accumulation of NFATc1-a is inhibition of
calcineurin binding.
Regulation of NFAT subcellular distribution by phosphor-
ylation. The NFAT transcription factors are phosphoproteins
that are located in the cytosol of resting cells. Upon dephos-
phorylation by the phosphatase calcineurin, NFAT accumu-
lates in the nucleus (12, 31). Conversely, phosphorylation of
NFAT isoforms opposes nuclear accumulation. NFAT phos-
phorylation has been shown to be mediated by many different
protein kinases (3, 5–7, 29, 34, 46). The relative importance
and physiological significance of each of the protein kinases
remains to be established.
The role of NFAT phosphorylation is unclear, but it is likely
that different sites of phosphorylation will regulate different
biological functions. Here we report that the phosphorylation
of NFATc1-a by JNK causes inhibition of calcineurin targeting
to the PxIxIT motif (Fig. 7). Previous studies indicate that
phosphorylation on the Ser-rich region facilitates intramolec-
ular interaction with the COOH-terminal nuclear localization
sequence (NLS2) of NFATc1 (4). Phosphorylation-dependent
intramolecular interaction within the NFAT homology region
has also been proposed to regulate NFATc3 subcellular distri-
bution (46). Furthermore, NFAT phosphorylation facilitates
intermolecular interaction with 14-3-3 adapter proteins (6).
Binding to 14-3-3 masks the NH2-terminal NLS1 and may
regulate NFAT subcellular distribution. These data indicate
that phosphorylation regulates multiple NFAT intermolecular
and intramolecular interactions that contribute to the shuttl-
ing of NFAT isoforms between the nuclear and cytoplasmic
compartments of the cell. Further studies of NFAT phosphor-
ylation are required before we can obtain a complete under-
standing of the mechanism of regulation of NFAT nuclear
accumulation.
Role of JNK-regulated NFATc1-a activity. NFATc1-a and
NFATc2 represent the major NFAT isoforms expressed by T
cells. NFATc1-a (Fig. 1), but not NFATc2 (7), is negatively
regulated by JNK. This observation raises an important ques-
tion concerning the physiological function of JNK as an NFAT
inhibitor. Studies of primary naive peripheral T cells indicate
that NFATc1-a is expressed at very low levels, but the expres-
sion of NFATc1-a is induced following T-cell activation (20,
33). In contrast, NFATc2 is expressed at high levels both be-
fore and after T-cell activation (20). This pattern of expression
suggests that JNK is not a significant regulator of NFAT ac-
tivity in naive T cells or in T cells at early times following
activation. However, a role for JNK as an inhibitor of NFAT
activity at late times following T-cell activation is implicated.
The possible role for JNK as an NFAT inhibitor at late times
following T-cell activation is consistent with the results of a
recent report that examined JNK expression by T cells (38).
JNK1 and JNK2 were found to be expressed at very low levels
in naive peripheral CD41 T cells. Similarly, the JNK activators
MKK4 and MKK7 were found to be expressed at low levels.
Activation mediated by the T-cell receptor plus the CD28
coreceptor caused a marked induction of mRNA and protein
expression of JNK1, JNK2, MKK4, and MKK7 that peaked at
approximately 24 h following T-cell activation. The peak of
expression correlated with increased JNK activity in the acti-
vated T cells. Together, these data indicate that the JNK sig-
naling pathway in T cells is induced during T-cell activation.
This temporal pattern of expression of the JNK signaling path-
way components is similar to that of NFATc1-a. The extremely
low level of expression of NFATc1-a and JNK pathway compo-
nents in naive peripheral CD41 T cells strongly argues against
a role for JNK during the early phase of T-cell activation.
The considerations outlined above indicate that the function
of JNK to inhibit NFATc1-a most likely occurs at late times
following T-cell activation (e.g., 24 h). We propose that JNK
functions to provide a tonic inhibitory signal that opposes
NFATc1-a activation and expression of downstream target
genes (e.g., IL-4). JNK may therefore provide a threshold for
the maintenance of T-cell responses by requiring higher levels
of stimulatory signals. This mechanism is consistent with the
observation that Jnk12/2 CD41 T cells are hyperresponsive to
stimulatory signals, including enhanced production of IL-4
(15). This role of JNK in setting a threshold for T-cell activa-
tion may contribute to tolerance and the initiation of an im-
mune response.
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